EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia

P Palmrich iD, E Kalafat iD, N Schirwani-Hartl, C Haberl iD, T Dorittke, L Steinmetz, L Krepler, J Binder iD

Ultrasound in Obstetrics & Gynecology · 2025

DOI: 10.1002/uog.70129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ultrasound in Obstetrics & Gynecology, 2025. Verfasst von P Palmrich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Pre-Eclampsia, Peptide Fragments. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), a marker of cardiac stress, has been proposed as a potential prognostic biomarker for maternal adverse outcome in pre‐eclampsia (PE). This study aimed to evaluate the predictive value of NT‐proBNP for severe maternal adverse outcome in pregnancies with an established diagnosis of PE.

Methods

This was a retrospective cohort study of singleton pregnancies diagnosed with PE ≤ 36 weeks of gestation that were assessed at the Medical University of Vienna between January 2018 and December 2023. Maternal serum levels of NT‐proBNP, soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and placental growth factor (PlGF) were measured at the time of PE diagnosis. The primary outcome was the occurrence of a severe maternal adverse event, including intensive care unit admission, maternal death, pulmonary edema and severe neurological complications. Associations between severe maternal adverse outcome and Z ‐scores for NT‐proBNP and the sFlt‐1/PlGF ratio were analyzed using logistic and Cox regression models adjusted for gestational age at sampling and the Z ‐score of the other biomarker. The area under the receiver‐operating‐characteristics (ROC) curve (AUC) was used to assess the discriminative ability of the biomarkers.

Results

Of 130 women included in our cohort, 13 (10%) experienced severe maternal adverse outcome. NT‐proBNP levels were significantly higher in this group (median, 688.0 (interquartile range (IQR), 249.6–1038.0) pg/mL vs 106.1 (IQR, 50.6–280.6) pg/mL; P < 0.001). Higher NT‐proBNP Z ‐score was associated significantly with severe maternal adverse outcome (adjusted odds ratio, 3.24 (95% CI, 1.50–7.84); P = 0.005) and predicted shorter time‐to‐delivery with severe maternal adverse outcome (adjusted hazard ratio, 3.08 (95% CI, 1.47–6.44); P = 0.003) after adjusting for gestational age at sampling and sFlt‐1/PlGF ratio Z ‐score. The sFlt‐1/PlGF ratio was not associated significantly with these outcomes. ROC‐curve analysis showed that NT‐proBNP had superior discriminative performance compared with the sFlt‐1/PlGF ratio (AUC, 0.75 (95% CI, 0.61–0.90) vs 0.67 (95% CI, 0.56–0.79)). The performance of both biomarkers improved when combined with gestational age at sampling (AUC, 0.82 (95% CI, 0.71–0.94) vs 0.76 (95% CI, 0.65–0.88)).

Conclusion

NT‐proBNP was a strong predictor of severe maternal adverse outcome and time‐to‐delivery in women diagnosed with PE, especially in early‐onset cases. NT‐proBNP may serve as a clinically accessible biomarker for risk stratification and surveillance in women with established PE. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Natriuretic Peptide, BrainPre-EclampsiaPeptide FragmentsHumansFemalePregnancyBiomarkersAdultRetrospective StudiesPrognosisPredictive Value of TestsPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1Gestational AgeROC CurvePregnancy Outcome

Stichwörter der Autor:innen

NT‐proBNPangiogenic markercardiovascular biomarkerpre‐eclampsia

Substanzen

Natriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Peptide FragmentsBiomarkersPlacenta Growth FactorVascular Endothelial Growth Factor Receptor-1PGF protein, humanFLT1 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Feto-Maternal Medicine, Medical University of Vienna, Vienna, Austria.
  • Department of Obstetrics and Gynecology, Koc University Hospital, Istanbul, Turkey.

ORCID-Profile: P Palmrich, E Kalafat, C Haberl, J Binder

Zitieren

APA

Palmrich, P., Kalafat, E., Schirwani-Hartl, N., Haberl, C., Dorittke, T., Steinmetz, L., Krepler, L., & Binder, J. (2025). Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia. Ultrasound in Obstetrics & Gynecology. https://doi.org/10.1002/uog.70129

Vancouver

Palmrich P, Kalafat E, Schirwani-Hartl N, Haberl C, Dorittke T, Steinmetz L, et al. Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia. Ultrasound in Obstetrics & Gynecology. 2025. doi:10.1002/uog.70129

BibTeX
@article{Palmrich2025,
  author = {Palmrich, P and Kalafat, E and Schirwani-Hartl, N and Haberl, C and Dorittke, T and Steinmetz, L and Krepler, L and Binder, J},
  title = {Prognostic value of maternal N‐terminal pro‐B‐type natriuretic peptide for prediction of severe maternal adverse outcome in women with pre‐eclampsia},
  journal = {Ultrasound in Obstetrics & Gynecology},
  year = {2025},
  doi = {10.1002/uog.70129}
}
Kostenlos starten →